Kratom Testing is critical in opioid treatment because kratom interacts wtih the brain’s opioid receptors, masks ongoing substance use and poses unique safety risks. Standard drug screens do not detect kratom, making specialized testing vital for accurate patient care.
How Kratom Affects Opioid Treatment
- Opioid receptor activity: Kratom contains compounds like mitragynine that bind to the same brain receptors as prescription opioids and heroin, producing similar physical dependence and withdrawal symptoms.
- Concealed use: Patients in recovery may use kratom to self-treat withdrawal or cravings, mistakenly believing it is a safe, natural alternative, which can prolong substance use disorders.
- Treatment interference: Unidentified kratom use can complicate medical stabilization, skew clinical evaluations, and alter how a care team manages medications like buprenorphine or methadone.
Why Specialized Testing Matters
- Invisible on standard panels: Routine 5-panel or 10-panel drug tests do not screen for the active alkaloids in kratom, allowing hidden use to go unnoticed during routine recovery monitoring.
- Targeted assays: Clinicians must order specialized urine or oral fluid tests that specifically look for mitragynine and 7-hydroxymitragynine to confirm use.
- Safe recovery plans: Identifying kratom use allows doctors to adjust treatment plans, offer targeted counseling, and address all active dependencies safely.
MedSTAT offers a rapid response Urine Dip Card with a 99%+ Accurate Analytical Sensitivity. This product is for Forensic Use Only.